Compare Hilton Hotels Corporation Common Stock (HLT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs TG Therapeutics Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $328 (market cap $73.63B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 8.9× TG Therapeutics Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HLT | TGTX | |
|---|---|---|
Market Cap | $73.63B | $8.26B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $59.06 |
52-Week Low | $256.75 | $26.39 |
Enterprise Value | $86.12B | $8.50B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide Holdings (HLT) trades at $323.22, up 0.59% with a bearish technical signal despite consistent earnings beats. The company shows strong fundamentals with 2025 revenue of $12.04B and net income of $1.46B, though valuation metrics appear elevated with a P/E of 49.06. Recent developments include brand expansion initiatives and upcoming Q2 2026 earnings on July 28, 2026.
Wall Street maintains a bullish outlook with 55% buy ratings and a $345.18 price target, representing 6.8% upside. Key risks include rising debt levels (debt-to-asset ratio increased to 73.88% in 2025) and technical weakness. The stock offers growth potential through Hilton's brand expansion but faces headwinds from high valuation and negative shareholder equity.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.
The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
